|
Precursor B-cell lymphoblastic leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
T cells modified to express chimeric antigen receptor (CAR) targeting CD19 (CD19CAR) have produced remarkable clinical responses in patients with relapsed/refractory B-cell acute lymphoblastic leukemia.
|
30979721 |
2019 |
|
Precursor B-cell lymphoblastic leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Cytokine release syndrome (CRS) remains to be a major adverse effect of chimeric antigen receptor T (CAR-T) cell therapy in B-cell acute lymphoblastic leukemia (B-ALL) and lymphoma.
|
30198955 |
2019 |
|
Precursor B-cell lymphoblastic leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
To address these issues experts representing the American Society for Blood and Marrow Transplant, the European Society for Blood and Marrow Transplantation, the International Society of Cell and Gene Therapy, and the Foundation for the Accreditation of Cellular Therapy formed a global CAR-T task force to identify and address key questions pertinent for hematologists and transplant physicians regarding the clinical use of anti CD19 CAR-T therapy in patients with B-ALL.
|
30576834 |
2019 |
|
Precursor B-cell lymphoblastic leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Recently two CAR-T cell based therapeutics, Kymriah (Tisagenlecleucel) and Yescarta (Axicabtagene ciloleucel) approved by US FDA (US Food and Drug Administration) are now used for treatment of B cell acute lymphoblastic leukemia (B-ALL) and diffuse large B-cell lymphoma (DLBCL) respectively in the US.
|
31754328 |
2019 |
|
Precursor B-cell lymphoblastic leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
To address these issues, experts representing the American Society for Blood and Marrow Transplant (ASBMT), the European Group for Blood and Marrow Transplantation (EBMT), the International Society of Cell and Gene Therapy (ISCT), and the Foundation for the Accreditation of Cellular Therapy (FACT), formed a global CAR-T task force to identify and address key questions pertinent for hematologists and transplant physicians regarding the clinical use of anti CD19 CAR-T therapy in patients with B-ALL.
|
31092900 |
2019 |
|
Precursor B-cell lymphoblastic leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
CAR simultaneously targeting CD19 and CD22 has the potential of inducing long-term remission in patients with B-ALL.
|
31182121 |
2019 |
|
Precursor B-cell lymphoblastic leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Novel immunotherapies targeting CD19, including the bispecific T-cell engager blinatumomab and chimeric antigen-receptor T (CAR-T) cells, have revolutionized the treatment of R/R B-ALL.
|
30695783 |
2019 |
|
Precursor B-cell lymphoblastic leukemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We evaluated the cost-effectiveness of CAR-T therapy among pediatric patients with relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL).
|
30551196 |
2018 |
|
Precursor B-cell lymphoblastic leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
The popularity of CAR-T has been founded on two CAR T-cell products recently approved by FDA (during 2017) in the treatment of relapsed/refractory B-cell acute lymphoblastic leukemia and B-cell lymphoma.
|
30181581 |
2018 |
|
Precursor B-cell lymphoblastic leukemia
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
CTL019 (tisagenlecleucel): CAR-T therapy for relapsed and refractory B-cell acute lymphoblastic leukemia.
|
30518999 |
2018 |
|
Precursor B-cell lymphoblastic leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
The Evolution and Future of CAR T Cells for B-Cell Acute Lymphoblastic Leukemia.
|
29171004 |
2018 |
|
Precursor B-cell lymphoblastic leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
CAR-T cells and allogeneic hematopoietic stem cell transplantation for relapsed/refractory B-cell acute lymphoblastic leukemia.
|
29032733 |
2017 |
|
Precursor B-cell lymphoblastic leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Recent progress in chimeric antigen receptor-modified T-cell (CAR-T cell) technology in cancer therapy is extremely promising, especially in the treatment of patients with B-cell acute lymphoblastic leukemia.
|
26961900 |
2016 |
|
Precursor B-cell lymphoblastic leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
Recently, complete clinical responses have been observed in small numbers of patients with B-ALL treated with adoptive immunotherapy using T cells genetically engineered to express chimeric antigen receptors (CARs) targeting CD19, a cell surface molecule present in essentially all cases of B-ALL.
|
24319203 |
2013 |
|
Precursor B-cell lymphoblastic leukemia
|
0.100 |
Biomarker
|
disease |
BEFREE |
CD19 CAR-targeted T cells induce long-term remission and B Cell Aplasia in an immunocompetent mouse model of B cell acute lymphoblastic leukemia.
|
23585892 |
2013 |
|
Precursor B-cell lymphoblastic leukemia
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
We have now generated CTL lines from peripheral blood (PB) or CB units that recognize multiple common viruses and provide antileukemic activity by transgenic expression of a chimeric antigen receptor (CAR) targeting CD19 expressed on B-ALL.
|
20110422 |
2010 |